Skip to main content
S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%
Smart Investors Daily
SID Premium
GM

NYSE · GMED

Globus Medical, Inc.

Healthcare · Medical - Devices

$71.05

Down-$10.39 (-12.76%)

Updated Nov 7, 2026, 5:31 AM

SID Score

5.0/10

Composite research score

Smart Money

62/100

Neutral

Market cap
11.89B
P/E ratio
28.2
Dividend yield
0.00%
52-week range
$60.36 – $101.40
Volume
9.27M
Avg. volume
1.73M

Price performance · GMED

GMED price history

1M range · 0 trading sessions · Daily adjusted prices

GMED does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GMED news

The latest Smart Investors Daily articles mentioning GMED.

Stock researchCompany · Overview

GMED research

Overview

Company profile and research snapshot.

Company profile

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$76.00
Implied upside
—
Analysts
—
GMED recent ratings
DateFirmRatingTarget
Nov 6, 2026Wells FargoOverweight—
Nov 6, 2026NeedhamBuy—
Nov 6, 2026BMO CapitalMarket Perform—
Oct 1, 2026RBC CapitalOutperform—
Aug 7, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 27, 2026

Globus Medical Record Q4 And Synergies Refocus Valuation And Growth Debate

Globus Medical (NYSE:GMED) reported record Q4 and full year results, supported by its U.S. Spine and Trauma businesses and Enabling Technologies segment. The company completed integrations of NuVasive and Nevro, with NuVasive synergies reaching $200 million nearly a year ahead of the original timetable. Globus Medical repaid acquired convertible debt and signaled plans to increase R&D and product development investment. For context, Globus Medical shares most recently traded at $96.71. The...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By